ATE401076T1 - Chinolinderivate als glucokinase liganden - Google Patents
Chinolinderivate als glucokinase ligandenInfo
- Publication number
- ATE401076T1 ATE401076T1 AT03773851T AT03773851T ATE401076T1 AT E401076 T1 ATE401076 T1 AT E401076T1 AT 03773851 T AT03773851 T AT 03773851T AT 03773851 T AT03773851 T AT 03773851T AT E401076 T1 ATE401076 T1 AT E401076T1
- Authority
- AT
- Austria
- Prior art keywords
- glucocinase
- ligands
- sup
- quinoline derivatives
- glucokinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0226931.4A GB0226931D0 (en) | 2002-11-19 | 2002-11-19 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401076T1 true ATE401076T1 (de) | 2008-08-15 |
Family
ID=9948090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03773851T ATE401076T1 (de) | 2002-11-19 | 2003-11-13 | Chinolinderivate als glucokinase liganden |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7230108B2 (de) |
| EP (1) | EP1583532B1 (de) |
| JP (1) | JP2006514626A (de) |
| AT (1) | ATE401076T1 (de) |
| AU (1) | AU2003282233A1 (de) |
| DE (1) | DE60322267D1 (de) |
| ES (1) | ES2307992T3 (de) |
| GB (1) | GB0226931D0 (de) |
| WO (1) | WO2004045614A1 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| FR2864535B1 (fr) * | 2003-12-24 | 2006-12-22 | Merck Sante Sas | Derives acides de quinoline et leurs applications en therapeutique |
| KR20070007104A (ko) * | 2004-02-18 | 2007-01-12 | 아스트라제네카 아베 | 화합물 |
| WO2005080359A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Benzamide derivatives and their use as glucokinae activating agents |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| MX2007004560A (es) * | 2004-10-16 | 2007-06-08 | Astrazeneca Ab | Proceso para hacer compuestos de fenoxi benzamida. |
| EP1891069A1 (de) * | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenylsubstituierte imidazol[4,5b]pyridin/pyrazin- und purinderivate als glucokinasemodulatoren |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| JP2009500442A (ja) * | 2005-07-09 | 2009-01-08 | アストラゼネカ アクチボラグ | ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物 |
| EP1902052B1 (de) * | 2005-07-09 | 2012-11-28 | AstraZeneca AB | Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes |
| EP1915367A1 (de) * | 2005-08-09 | 2008-04-30 | AstraZeneca AB | Heteroarylcarbamoylbenzolderivate zur behandlung von diabetes |
| US9202182B2 (en) * | 2005-08-11 | 2015-12-01 | International Business Machines Corporation | Method and system for analyzing business architecture |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| WO2007039177A2 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| JP5137207B2 (ja) * | 2005-11-01 | 2013-02-06 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化因子 |
| TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2007122482A1 (en) * | 2006-04-20 | 2007-11-01 | Pfizer Products Inc. | Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| WO2007143434A2 (en) | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents |
| TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| TW200825060A (en) * | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| EP2091947A2 (de) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinaseaktivatoren |
| EP2121666A1 (de) | 2006-12-21 | 2009-11-25 | AstraZeneca AB | Als glk-aktivator geeignete neue kristalline verbindung |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| CA2732165A1 (en) | 2008-08-04 | 2010-02-11 | Astrazeneca Ab | Therapeutic agents 414 |
| JP5575137B2 (ja) | 2008-10-22 | 2014-08-20 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗糖尿病剤として有用な新規な環状ベンゾイミダゾール誘導体 |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
| WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| EP2424529B1 (de) | 2009-04-30 | 2016-12-28 | Midwestern University | Neue therapeutische behandlungen mit centhaquin |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US8940765B2 (en) | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
| EP2880028B1 (de) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetische tricyclische verbindungen |
| BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CA2960324A1 (en) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298A4 (de) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetische spirochromanverbindungen |
| TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| EP3609869A1 (de) | 2017-04-10 | 2020-02-19 | Bayer Aktiengesellschaft | Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1561350A (en) | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
| US5792109A (en) | 1994-09-01 | 1998-08-11 | Leland L. Ladd | Irrigation pump and system |
| JPH08301760A (ja) | 1995-05-10 | 1996-11-19 | Shiseido Co Ltd | 皮膚外用剤 |
| JP3168915B2 (ja) | 1995-05-25 | 2001-05-21 | 田辺製薬株式会社 | 医薬組成物 |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | ５−アミノイソキサゾール誘導体 |
| GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| CZ301366B6 (cs) | 1999-03-29 | 2010-02-03 | F. Hoffmann-La Roche Ag | 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem |
| GB9921684D0 (en) | 1999-09-15 | 1999-11-17 | Zeneca Ltd | Assays |
| AU780787B2 (en) | 1999-09-17 | 2005-04-14 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| BR0110573A (pt) | 2000-05-03 | 2003-04-01 | Hoffmann La Roche | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto |
| PT1280801E (pt) | 2000-05-03 | 2005-11-30 | Hoffmann La Roche | Activadores da glucoquinase que contem hidantoina |
| JP3971189B2 (ja) | 2000-05-08 | 2007-09-05 | エフ．ホフマン−ラ ロシュ アーゲー | ｐ−アミノ置換フェニルアミドグルコキナーゼ活性化物質 |
| ES2230309T3 (es) | 2000-05-08 | 2005-05-01 | F. Hoffmann-La Roche Ag | Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa. |
| PT1296967E (pt) | 2000-06-28 | 2006-10-31 | Amgen Inc | Moduladores benzotiazolilo de ppar-gama |
| WO2002008209A1 (en) | 2000-07-20 | 2002-01-31 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| JP4911866B2 (ja) | 2000-09-25 | 2012-04-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼ阻害剤としてのファルネシルトランスフェラーゼを阻害するキノリンおよびキナゾリン誘導体 |
| BR0115999A (pt) * | 2000-12-06 | 2003-09-30 | Hoffmann La Roche | Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| BR0212477A (pt) | 2001-09-12 | 2004-08-24 | Upjohn Co | 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças |
| US7544690B2 (en) | 2001-10-01 | 2009-06-09 | Taisho Pharmaceutical Co., Ltd. | MCH receptor antagonists |
| EP1336607A1 (de) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amidderivate als Glucokinase-Aktivatoren |
| AU2002349299A1 (en) | 2001-12-03 | 2003-06-17 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| AU2002365611A1 (en) | 2001-12-05 | 2003-06-17 | F. Hoffmann - La Roche Ag | Inflammation modulators |
| US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
| HUP0402309A3 (en) | 2001-12-21 | 2008-09-29 | Novo Nordisk As | Amide derivatives as glucokinase activators and pharmaceutical compositions containing them |
| AU2003221140B9 (en) | 2002-03-26 | 2009-07-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| CN100357283C (zh) | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | 一类甲硫氨酰氨肽酶抑制剂 |
| BR0309546A (pt) | 2002-04-26 | 2005-02-15 | Hoffmann La Roche | Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii |
| EP1518925A4 (de) | 2002-05-16 | 2006-01-04 | Banyu Pharma Co Ltd | Glucokinase-proteinkristall und verfahren zur arzneistoffkonstruktion unter verwendung des kristalls |
| MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
| ES2293005T3 (es) | 2002-10-03 | 2008-03-16 | F. Hoffmann-La Roche Ag | Indol-3-carboxamidas como activadores de la glucocinasa. |
| AU2003302279B2 (en) | 2002-10-03 | 2008-06-12 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of Type 2 diabetes |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| JP4716734B2 (ja) | 2003-01-06 | 2011-07-06 | イーライ リリー アンド カンパニー | グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド |
| AU2003294376A1 (en) | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| WO2004072066A1 (en) | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| PE20050194A1 (es) | 2003-02-13 | 2005-04-23 | Banyu Pharma Co Ltd | Derivados de piridina-2-carboxamida como activadores de glucoquinasa |
| CN101712657A (zh) | 2003-02-26 | 2010-05-26 | 万有制药株式会社 | 杂芳基氨基甲酰基苯衍生物 |
| US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
| GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
| EP1532980A1 (de) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-Heteroaryl Indol-Carboxamide und deren analoga zur Vewendung als glucokinase Aktivatoren zur Behandlung von Diabetes |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0327760D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| WO2005063738A1 (ja) | 2003-12-29 | 2005-07-14 | Banyu Pharmaceutical Co.,Ltd | 新規２－へテロアリール置換ベンズイミダゾール誘導体 |
| RU2386622C9 (ru) | 2004-01-06 | 2021-04-21 | Ново Нордиск А/С | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы |
| WO2005080359A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Benzamide derivatives and their use as glucokinae activating agents |
| KR20070007104A (ko) | 2004-02-18 | 2007-01-12 | 아스트라제네카 아베 | 화합물 |
| WO2005090332A1 (ja) | 2004-03-23 | 2005-09-29 | Banyu Pharmaceutical Co., Ltd | 置換キナゾリン又はピリドピリミジン誘導体 |
| US7781451B2 (en) | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| AU2005229416B2 (en) | 2004-04-02 | 2009-03-26 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes |
| MXPA06012008A (es) | 2004-04-21 | 2007-01-25 | Prosidion Ltd | Compuestos de amida tri(ciclo) sustituidos. |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| EP1758611A2 (de) | 2004-06-17 | 2007-03-07 | Novo Nordisk A/S | Verwendung von leberselektiven glukokinase-aktivatoren |
| GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| GB0418058D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
| AU2005271016A1 (en) | 2004-08-12 | 2006-02-16 | Prosidion Limited | Substituted phenylacetamides and their use as glucokinase activators |
| GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| MX2007004560A (es) | 2004-10-16 | 2007-06-08 | Astrazeneca Ab | Proceso para hacer compuestos de fenoxi benzamida. |
| GB0423043D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
-
2002
- 2002-11-19 GB GBGB0226931.4A patent/GB0226931D0/en not_active Ceased
-
2003
- 2003-11-13 AT AT03773851T patent/ATE401076T1/de not_active IP Right Cessation
- 2003-11-13 DE DE60322267T patent/DE60322267D1/de not_active Expired - Fee Related
- 2003-11-13 JP JP2004552854A patent/JP2006514626A/ja not_active Withdrawn
- 2003-11-13 ES ES03773851T patent/ES2307992T3/es not_active Expired - Lifetime
- 2003-11-13 EP EP03773851A patent/EP1583532B1/de not_active Expired - Lifetime
- 2003-11-13 US US10/534,651 patent/US7230108B2/en not_active Expired - Fee Related
- 2003-11-13 WO PCT/GB2003/004915 patent/WO2004045614A1/en active IP Right Grant
- 2003-11-13 AU AU2003282233A patent/AU2003282233A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1583532B1 (de) | 2008-07-16 |
| US7230108B2 (en) | 2007-06-12 |
| AU2003282233A1 (en) | 2004-06-15 |
| DE60322267D1 (de) | 2008-08-28 |
| ES2307992T3 (es) | 2008-12-01 |
| EP1583532A1 (de) | 2005-10-12 |
| US20060079553A1 (en) | 2006-04-13 |
| JP2006514626A (ja) | 2006-05-11 |
| GB0226931D0 (en) | 2002-12-24 |
| WO2004045614A1 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE401076T1 (de) | Chinolinderivate als glucokinase liganden | |
| GB0226930D0 (en) | Chemical compounds | |
| CY1115117T1 (el) | Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα | |
| CY1107539T1 (el) | Παραγωγα κουιναζολινης | |
| ATE264846T1 (de) | Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen | |
| ATE344033T1 (de) | Vinylphenyl-derivate als glk-aktivatoren | |
| JO2282B1 (en) | Oxazole derivatives | |
| EA200300323A1 (ru) | ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ) | |
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| HRP20090281T1 (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
| NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
| MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
| DE60045508D1 (de) | Dalda-analoge und ihre verwendung | |
| ECSP055809A (es) | Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| EA200200742A1 (ru) | 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии | |
| ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| DE60119368D1 (de) | Zusammensetzung enthaltend einen angiotensin-ii-rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck | |
| MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
| DE60128100D1 (de) | Analgetisches arzneimittel | |
| ATE259813T1 (de) | Triazolopyrimidinderivate | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
| PE20030236A1 (es) | Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |